{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:51:47Z","timestamp":1791640307315,"version":"4.3.4"},"reference-count":137,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"an Early Career Fellowship from the National Health and Medical Research Council"},{"name":"Viertel Clinical Investigator Award from the Sylvia and Charles Viertel Charitable Foundation"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.eplepsyres.2019.03.001","type":"journal-article","created":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T17:20:08Z","timestamp":1551720008000},"page":"18-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":113,"special_numbering":"C","title":["Identifying mutations in epilepsy genes: Impact on treatment selection"],"prefix":"10.1016","volume":"152","author":[{"given":"Piero","family":"Perucca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Perucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.seizure.2017.11.017","article-title":"Does age affect response to quinidine in patients with KCNT1 mutations? Report of three new cases and review of the literature","volume":"55","author":"Abdelnour","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0010","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41598-017-00115-w","article-title":"Epilepsy associated GRIN2A mutations reduce NMDA receptor trafficking and agonist potency\u2013molecular profiling and functional rescue","volume":"7","author":"Addis","year":"2017","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.eplepsyres.2019.03.001_bib0015","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/ana.25248","article-title":"De novo gain-of-function variants in KCNT2 as a novel cause of developmental and epileptic encephalopathy","volume":"83","author":"Ambrosino","year":"2018","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.eplepsyres.2019.03.001_bib0020","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/epi.14037","article-title":"A comprehensive approach to identifying repurposed drugs to treat SCN8A epilepsy","volume":"59","author":"Atkin","year":"2018","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.eplepsyres.2019.03.001_bib0025","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/epi.14196","article-title":"The novel sodium channel modulator GS-458967 (GS967) is an effective treatment in a mouse model of SCN8A encephalopathy","volume":"59","author":"Baker","year":"2018","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.eplepsyres.2019.03.001_bib0030","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41436-018-0060-2","article-title":"The landscape of epilepsy-related GATOR1 variants","volume":"21","author":"Baldassari","year":"2019","journal-title":"Genet. Med."},{"issue":"9","key":"10.1016\/j.eplepsyres.2019.03.001_bib0035","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/epi.13461","article-title":"The SCN8A encephalopathy mutation p.Ile1327Val displays elevated sensitivity to the anticonvulsant phenytoin","volume":"57","author":"Barker","year":"2016","journal-title":"Epilepsia"},{"issue":"November (5)","key":"10.1016\/j.eplepsyres.2019.03.001_bib0040","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1136\/adc.81.5.431","article-title":"Epidemiology of pyridoxine dependent and pyridoxine responsive seizures in the UK","volume":"81","author":"Baxter","year":"1999","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0045","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/ana.24229","article-title":"Targeted treatment of migrating partial seizures of infancy with quinidine","volume":"76","author":"Bearden","year":"2014","journal-title":"Ann. Neurol."},{"issue":"10","key":"10.1016\/j.eplepsyres.2019.03.001_bib0050","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1111\/epi.14555","article-title":"Progress report on new antiepileptic drugs: a summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). II. Drugs in more advanced clinical development","volume":"59","author":"Bialer","year":"2018","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.eplepsyres.2019.03.001_bib0055","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1111\/epi.14557","article-title":"Progress report on new antiepileptic drugs: a summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). II. Drugs in preclinical and early clinical development","volume":"59","author":"Bialer","year":"2018","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.eplepsyres.2019.03.001_bib0060","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s13311-015-0372-8","article-title":"Remarkable phenytoin sensitivity in 4 children with SCN8A-related epilepsy: a molecular neuropharmacological approach","volume":"13","author":"Boerma","year":"2016","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1016\/j.eplepsyres.2019.03.001_bib0065","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/epi4.12059","article-title":"Phenytoin as a last-resort treatment in SCN8A encephalopathy","volume":"2","author":"Braakman","year":"2017","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0070","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1684\/epd.2015.0754","article-title":"Treatable newborn and infant seizures due to inborn errors of metabolism","volume":"17","author":"Campistol","year":"2015","journal-title":"Epileptic Disord."},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0075","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.cophys.2017.12.007","article-title":"Dravet syndrome: a sodium channel interneuronopathy","volume":"2","author":"Catterall","year":"2018","journal-title":"Curr. Opin. Physiol."},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0080","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1113\/jphysiol.2010.187484","article-title":"NaV1.1 channels and epilepsy","volume":"588","author":"Catterall","year":"2010","journal-title":"J. Physiol."},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0085","doi-asserted-by":"crossref","first-page":"14646","DOI":"10.1073\/pnas.1211591109","article-title":"Specific deletion of NaV1.1 sodium channels in inhibitory interneurons causes seizures and premature death in a mouse model of Dravet syndrome","volume":"109","author":"Cheah","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9242","key":"10.1016\/j.eplepsyres.2019.03.001_bib0090","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(00)03157-3","article-title":"Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group","volume":"356","author":"Chiron","year":"2000","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.eplepsyres.2019.03.001_bib0095","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3988\/jcn.2018.14.1.22","article-title":"Efficacy of stiripentol in Dravet syndrome with or without SCN1A mutations","volume":"14","author":"Cho","year":"2018","journal-title":"J. Clin. Neurol."},{"issue":"3","key":"10.1016\/j.eplepsyres.2019.03.001_bib0100","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/ana.24598","article-title":"Ineffective quinidine therapy in early onset epileptic encephalopathy with KCNT1 mutation","volume":"79","author":"Chong","year":"2016","journal-title":"Ann. Neurol."},{"issue":"10","key":"10.1016\/j.eplepsyres.2019.03.001_bib0105","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.seizure.2013.07.003","article-title":"GLUT1 deficiency syndrome 2013: current state of the art","volume":"22","author":"De Giorgis","year":"2013","journal-title":"Seizure"},{"issue":"1-2","key":"10.1016\/j.eplepsyres.2019.03.001_bib0110","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0014-2999(94)90022-1","article-title":"Excitatory amino acid neurotransmission through both NMDA and non-NMDA receptors is involved in the anticonvulsant activity of felbamate in DBA\/2 mice","volume":"262","author":"De Sarro","year":"1994","journal-title":"Eur. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.eplepsyres.2019.03.001_bib0115","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1007\/s11064-017-2312-y","article-title":"Genomics-guided precise anti-epileptic drug development","volume":"42","author":"Delanty","year":"2017","journal-title":"Neurochem. Res."},{"issue":"5","key":"10.1016\/j.eplepsyres.2019.03.001_bib0120","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1111\/epi.13366","article-title":"Kv7.2 mutation associated with early onset epileptic encephalopathy with suppression-burst enhances Kv7\/M channel activity","volume":"57","author":"Devaux","year":"2016","journal-title":"Epilepsia"},{"issue":"21","key":"10.1016\/j.eplepsyres.2019.03.001_bib0125","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.eplepsyres.2019.03.001_bib0130","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.braindev.2016.10.015","article-title":"Efficacy of sodium channel blockers in SCN2A early infantile epileptic encephalopathy","volume":"39","author":"Dilena","year":"2017","journal-title":"Brain Dev."},{"issue":"4","key":"10.1016\/j.eplepsyres.2019.03.001_bib0135","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1007\/s13311-018-0657-9","article-title":"Early treatment with quinidine in 2 patients with epilepsy of infancy with migrating focal seizures (EIMFS) due to gain-of-function KCNT1 mutations: functional studies, clinical responses, and critical issues for personalized therapy","volume":"15","author":"Dilena","year":"2018","journal-title":"Neurotherapeutics"},{"issue":"6","key":"10.1016\/j.eplepsyres.2019.03.001_bib0140","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0022-3476(99)70307-0","article-title":"Demographics and diagnosis of pyridoxine-dependent seizures","volume":"134","author":"Ebinger","year":"1999","journal-title":"J. Pediatr."},{"issue":"12","key":"10.1016\/j.eplepsyres.2019.03.001_bib0145","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S1474-4422(15)00199-4","article-title":"A roadmap for precision medicine in the epilepsies","volume":"14","author":"EpiPM Consortium","year":"2015","journal-title":"Lancet Neurol."},{"issue":"9","key":"10.1016\/j.eplepsyres.2019.03.001_bib0150","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1111\/j.1528-1167.2010.02640.x","article-title":"Sodium channel SCN1A and epilepsy: mutations and mechanisms","volume":"51","author":"Escayg","year":"2010","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.eplepsyres.2019.03.001_bib0155","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2217\/pgs.12.31","article-title":"Discovery of epilepsy susceptibility genes: implications for therapy development and pharmacogenomics","volume":"13","author":"Ferraro","year":"2012","journal-title":"Pharmacogenomics"},{"issue":"5","key":"10.1016\/j.eplepsyres.2019.03.001_bib0160","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1684\/epd.2018.1001","article-title":"Lacosamide for SCN2A-related intractable neonatal and infantile seizures","volume":"20","author":"Flor-Hirsch","year":"2018","journal-title":"Epileptic Disord."},{"issue":"10","key":"10.1016\/j.eplepsyres.2019.03.001_bib0165","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1586\/14737175.2015.1083424","article-title":"The pharmacogenomics of epilepsy","volume":"15","author":"Franco","year":"2015","journal-title":"Expert Rev. Neurother."},{"issue":"3","key":"10.1016\/j.eplepsyres.2019.03.001_bib0170","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/ajmg.c.31655","article-title":"mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex","volume":"178","author":"Franz","year":"2018","journal-title":"Am. J. Med. Genet. C Semin. Med. Genet."},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0175","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"French","year":"2016","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.eplepsyres.2019.03.001_bib0180","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/ejn.13923","article-title":"Treatment with the GSK3-beta inhibitor Tideglusib improves hippocampal development and memory performance in juvenile, but not adult, Cdkl5 knockout mice","volume":"47","author":"Fuchs","year":"2018","journal-title":"Eur. J. Neurosci."},{"issue":"1","key":"10.1016\/j.eplepsyres.2019.03.001_bib0185","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.braindev.2016.08.002","article-title":"Quinidine therapy for West syndrome with KCNTI mutation: a case report","volume":"39","author":"Fukuoka","year":"2017","journal-title":"Brain Dev."},{"issue":"12","key":"10.1016\/j.eplepsyres.2019.03.001_bib0190","doi-asserted-by":"crossref","first-page":"e1112","DOI":"10.1212\/WNL.0000000000006199","article-title":"The phenotype of SCN8A developmental and epileptic encephalopathy","volume":"91","author":"Gardella","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0195","series-title":"GeneReviews\u00ae","article-title":"KCNT1-related epilepsy","author":"Gertler","year":"2018"},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0200","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1528-1157.1998.tb01413.x","article-title":"Lamotrigine and seizure aggravation in severe myoclonic epilepsy","volume":"9","author":"Guerrini","year":"1998","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.eplepsyres.2019.03.001_bib0205","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.celrep.2017.09.088","article-title":"A de novo mutation in the sodium-activated potassium channel KCNT2 alters ion selectivity and causes epileptic encephalopathy","volume":"21","author":"Gururaj","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0210","series-title":"GeneReviews\u00ae","article-title":"SCN8A-related epilepsy with encephalopathy","author":"Hammer","year":"2016"},{"issue":"6","key":"10.1016\/j.eplepsyres.2019.03.001_bib0215","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/epi.13381","article-title":"Primer Part 1-The building blocks of epilepsy genetics","volume":"57","author":"Helbig","year":"2016","journal-title":"Epilepsia"},{"issue":"11","key":"10.1016\/j.eplepsyres.2019.03.001_bib0220","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1212\/WNL.0000000000001926","article-title":"SCN2A encephalopathy: a major cause of epilepsy of infancy with migrating focal seizures","volume":"85","author":"Howell","year":"2015","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.eplepsyres.2019.03.001_bib0225","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1528-1157.1990.tb05494.x","article-title":"Epidemiology of severe myoclonic epilepsy of infancy","volume":"31","author":"Hurst","year":"1990","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.eplepsyres.2019.03.001_bib0230","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1038\/s41467-018-07524-z","article-title":"Genome-wide mega-analysis identifies 16 loci and highlights diverse biological mechanisms in the common epilepsies","volume":"10","author":"International League against Epilepsy Consortium on Complex Epilepsies","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0235","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ejpn.2011.03.010","article-title":"Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex","volume":"15","author":"J\u00f3\u017awiak","year":"2011","journal-title":"Eur. J. Paediatr."},{"issue":"Pt 10","key":"10.1016\/j.eplepsyres.2019.03.001_bib0240","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1093\/brain\/awt233","article-title":"Epilepsy, hippocampal sclerosis and febrile seizures linked by common genetic variation around SCN1A","volume":"136","author":"Kasperaviciute","year":"2013","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.eplepsyres.2019.03.001_bib0245","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/jnr.23423","article-title":"Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease)","volume":"92","author":"Katz","year":"2014","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0250","first-page":"h4633","article-title":"Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study","volume":"351","author":"Kesselheim","year":"2015","journal-title":"B.M.J."},{"issue":"5","key":"10.1016\/j.eplepsyres.2019.03.001_bib0255","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1055\/s-2005-872843","article-title":"Seizure control and acceptance of the ketogenic diet in GLUT1 deficiency syndrome: a 2- to 5-year follow-up of 15 children enrolled prospectively","volume":"36","author":"Klepper","year":"2005","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0260","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3389\/fneur.2018.00530","article-title":"The efficacy of ketogenic diet for specific genetic mutation in developmental and epileptic encephalopathy","volume":"9","author":"Ko","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0265","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.eplepsyres.2018.02.003","article-title":"Targeted gene panel and genotype-phenotype correlation in children with developmental and epileptic encephalopathy","volume":"141","author":"Ko","year":"2018","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2018.06.010","article-title":"The glucose transporter type 1 (Glut1) syndromes","author":"Koch","year":"2019","journal-title":"Epilepsy Behav."},{"issue":"5","key":"10.1016\/j.eplepsyres.2019.03.001_bib0275","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1212\/WNL.0000000000001211","article-title":"The phenotypic spectrum of SCN8A encephalopathy","volume":"84","author":"Larsen","year":"2015","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.eplepsyres.2019.03.001_bib0280","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1111\/epi.13222","article-title":"The role of SLC2A1 mutations in myoclonic astatic epilepsy and absence epilepsy, and the estimated frequency of GLUT1 deficiency syndrome","volume":"56","author":"Larsen","year":"2015","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.eplepsyres.2019.03.001_bib0285","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ajhg.2016.07.013","article-title":"GRIN2D recurrent de novo dominant mutation causes a severe epileptic encephalopathy treatable with NMDA receptor channel blockers","volume":"99","author":"Li","year":"2016","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0290","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/jmedgenet-2015-103508","article-title":"KCNT1 mutations in seizure disorders: the phenotypic spectrum and functional effects","volume":"53","author":"Lim","year":"2016","journal-title":"J. Med. Genet."},{"issue":"8","key":"10.1016\/j.eplepsyres.2019.03.001_bib0295","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/epi.13813","article-title":"Use of the ketogenic diet to manage refractory epilepsy in CDKL5 disorder: experience of &100 patients","volume":"58","author":"Lim","year":"2017","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.eplepsyres.2019.03.001_bib0300","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/brain\/awy326","article-title":"Neuronal mechanisms of mutations in SCN8A causing epilepsy or intellectual disability","volume":"142","author":"Liu","year":"2019","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.eplepsyres.2019.03.001_bib0305","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.braindev.2017.09.008","article-title":"A quinidine non responsive novel KCNT1 mutation in an Indian infant with epilepsy of infancy with migrating focal seizures","volume":"40","author":"Madaan","year":"2018","journal-title":"Brain Dev."},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0310","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00424-010-0831-3","article-title":"KV7 channelopathies","volume":"460","author":"Maljevic","year":"2010","journal-title":"Pflugers Arch."},{"issue":"50","key":"10.1016\/j.eplepsyres.2019.03.001_bib0315","doi-asserted-by":"crossref","first-page":"18177","DOI":"10.1073\/pnas.0506818102","article-title":"Identification of an Nav1.1 sodium channel (SCN1A) loss-of-function mutation associated with familial simple febrile seizures","volume":"102","author":"Mantegazza","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.eplepsyres.2019.03.001_bib0320","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s40265-017-0771-8","article-title":"Cerliponase alfa: first global approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.eplepsyres.2019.03.001_bib0325","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/nan.12463","article-title":"Review: mechanistic target of rapamycin (mTOR) pathway, focal cortical dysplasia and epilepsy","volume":"44","author":"Marsan","year":"2018","journal-title":"Neuropathol. Appl. Neurobiol."},{"issue":"3","key":"10.1016\/j.eplepsyres.2019.03.001_bib0330","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S1474-4422(15)00250-1","article-title":"The genetic landscape of the epileptic encephalopathies of infancy and childhood","volume":"15","author":"McTague","year":"2016","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.eplepsyres.2019.03.001_bib0335","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1212\/WNL.0000000000004762","article-title":"Clinical and molecular characterization of KCNT1-related severe early-onset epilepsy","volume":"90","author":"McTague","year":"2018","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.eplepsyres.2019.03.001_bib0340","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s40291-017-0257-0","article-title":"The impact of next-generation sequencing on the diagnosis and treatment of epilepsy in paediatric patients","volume":"21","author":"Mei","year":"2017","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0345","series-title":"GeneReviews\u00ae","article-title":"KCNQ3-related disorders","author":"Miceli","year":"2017"},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0350","series-title":"GeneReviews\u00ae","article-title":"KCNQ2-related disorders","author":"Miceli","year":"2018"},{"issue":"23","key":"10.1016\/j.eplepsyres.2019.03.001_bib0355","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.2174\/0929867324666171012122852","article-title":"Pharmacological targeting of neuronal Kv7.2\/3 channels: a focus on chemotypes and receptor sites","volume":"25","author":"Miceli","year":"2018","journal-title":"Curr. Med. Chem."},{"issue":"6","key":"10.1016\/j.eplepsyres.2019.03.001_bib0360","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/ana.24520","article-title":"Quinidine in the treatment of KCNT1-positive epilepsies","volume":"78","author":"Mikati","year":"2015","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0365","series-title":"GeneReviews\u00ae","article-title":"SCN1A-related seizure disorders","author":"Miller","year":"2018"},{"issue":"5","key":"10.1016\/j.eplepsyres.2019.03.001_bib0370","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1212\/NXG.0000000000000096","article-title":"KCNQ2 encephalopathy: features, mutational hot spots, and ezogabine treatment of 11 patients","volume":"2","author":"Millichap","year":"2016","journal-title":"Neurol. Genet."},{"issue":"1","key":"10.1016\/j.eplepsyres.2019.03.001_bib0375","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1111\/epi.13601","article-title":"Infantile spasms and encephalopathy without preceding neonatal seizures caused by KCNQ2 R198Q, a gain-of-function variant","volume":"58","author":"Millichap","year":"2017","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.eplepsyres.2019.03.001_bib0380","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ana.24128","article-title":"KCNT1 gain-of-function in 2 epilepsy phenotypes is reversed by quinidine","volume":"75","author":"Milligan","year":"2014","journal-title":"Ann. Neurol."},{"issue":"Pt 5","key":"10.1016\/j.eplepsyres.2019.03.001_bib0385","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1093\/brain\/awu051","article-title":"Epilepsy due to PNPO mutations: genotype, environment and treatment affect presentation and outcome","volume":"137","author":"Mills","year":"2014","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.eplepsyres.2019.03.001_bib0390","first-page":"527","article-title":"Identifying new antiepileptic drugs through genomics-based drug repurposing","volume":"26","author":"Mirza","year":"2017","journal-title":"Hum. Mol. Genet."},{"issue":"1","key":"10.1016\/j.eplepsyres.2019.03.001_bib0395","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1212\/WNL.0000000000004769","article-title":"Precision therapy for epilepsy due to KCNT1 mutations: a randomized trial of oral quinidine","volume":"90","author":"Mullen","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.eplepsyres.2019.03.001_bib0400","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejpn.2015.09.001","article-title":"Retrospective evaluation of low long-term efficacy of antiepileptic drugs and ketogenic diet in 39 patients with CDKL5-related epilepsy","volume":"20","author":"M\u00fcller","year":"2016","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0405","series-title":"GeneReviews\u00ae","article-title":"GRIN2A-related speech disorders and epilepsy","author":"Myers","year":"2016"},{"issue":"4","key":"10.1016\/j.eplepsyres.2019.03.001_bib0410","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1684\/epd.2018.0985","article-title":"Genetic literacy series: genetic epilepsy with febrile seizures plus","volume":"20","author":"Myers","year":"2018","journal-title":"Epileptic Disord."},{"issue":"45","key":"10.1016\/j.eplepsyres.2019.03.001_bib0415","doi-asserted-by":"crossref","first-page":"18577","DOI":"10.1073\/pnas.1209142109","article-title":"Modulation of voltage-gated K+ channels by the sodium channel \u03b21 subunit","volume":"109","author":"Nguyen","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.eplepsyres.2019.03.001_bib0420","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1177\/1073858418763752","article-title":"Potassium channel gain-of-function in epilepsy: an unresolved paradox","volume":"24","author":"Niday","year":"2018","journal-title":"Neuroscientist"},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0425","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1212\/WNL.0000000000000060","article-title":"KCNQ2 encephalopathy: delineation of the electroclinical phenotype and treatment response","volume":"82","author":"Numis","year":"2014","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.eplepsyres.2019.03.001_bib0430","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1111\/epi.14551","article-title":"Lack of response to quinidine in KCNT1-related neonatal epilepsy","volume":"59","author":"Numis","year":"2018","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.eplepsyres.2019.03.001_bib0435","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/ana.24080","article-title":"Dominant-negative effects of KCNQ2 mutations are associated with epileptic encephalopathy","volume":"75","author":"Orhan","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0440","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1749-6632.1991.tb37754.x","article-title":"Epidemiology of tuberous sclerosis","volume":"615","author":"Osborne","year":"1991","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"32","key":"10.1016\/j.eplepsyres.2019.03.001_bib0445","doi-asserted-by":"crossref","first-page":"7643","DOI":"10.1523\/JNEUROSCI.2709-16.2017","article-title":"Aberrant sodium channel currents and hyperexcitability of medial entorhinal cortex neurons in a mouse model of SCN8A encephalopathy","volume":"37","author":"Ottolini","year":"2017","journal-title":"J. Neurosci."},{"issue":"10","key":"10.1016\/j.eplepsyres.2019.03.001_bib0450","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1523\/JNEUROSCI.4314-05.2006","article-title":"A common ankyrin-G-based mechanism retains KCNQ and NaV channels at electrically active domains of the axon","volume":"26","author":"Pan","year":"2006","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.eplepsyres.2019.03.001_bib0455","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/humu.23149","article-title":"Diagnostic targeted resequencing in 349 patients with drug-resistant pediatric epilepsies identifies causative mutations in 30 different genes","volume":"38","author":"Parrini","year":"2017","journal-title":"Hum. Mutat."},{"issue":"1","key":"10.1016\/j.eplepsyres.2019.03.001_bib0460","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/cns.12869","article-title":"Next-generation sequencing improves treatment efficacy and reduces hospitalization in children with drug-resistant epilepsy","volume":"25","author":"Peng","year":"2019","journal-title":"CNS Neurosci. Ther."},{"issue":"6","key":"10.1016\/j.eplepsyres.2019.03.001_bib0465","doi-asserted-by":"crossref","first-page":"356","DOI":"10.5698\/1535-7597.18.6.356","article-title":"Genetics of focal epilepsies: What do we know and where are we heading?","volume":"18","author":"Perucca","year":"2018","journal-title":"Epilepsy Curr."},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0470","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2017.02.001","article-title":"Real-world utility of whole exome sequencing with targeted gene analysis for focal epilepsy","volume":"131","author":"Perucca","year":"2017","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0475","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/acn3.39","article-title":"GRIN2A mutation and early-onset epileptic encephalopathy: personalized therapy with memantine","volume":"1","author":"Pierson","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"5","key":"10.1016\/j.eplepsyres.2019.03.001_bib0480","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/epi.12984","article-title":"Early and effective treatment of KCNQ2 encephalopathy","volume":"56","author":"Pisano","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0485","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1136\/jmedgenet-2016-104509","article-title":"GRIN2 B encephalopathy: novel findings on phenotype, variant clustering, functional consequences and treatment aspects","volume":"54","author":"Platzer","year":"2017","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0490","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/B978-0-444-59565-2.00050-2","article-title":"Pyridoxine and pyridoxalphosphate-dependent epilepsies","volume":"113","author":"Plecko","year":"2013","journal-title":"Handb. Clin. Neurol."},{"issue":"16","key":"10.1016\/j.eplepsyres.2019.03.001_bib0495","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1212\/WNL.0000000000000344","article-title":"Pyridoxine responsiveness in novel mutations of the PNPO gene","volume":"82","author":"Plecko","year":"2014","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.eplepsyres.2019.03.001_bib0500","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.3928\/19382359-20170320-01","article-title":"Tuberous sclerosis complex: a review","volume":"46","author":"Randle","year":"2017","journal-title":"Pediatr. Ann."},{"issue":"4","key":"10.1016\/j.eplepsyres.2019.03.001_bib0505","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/14737175.2017.1253476","article-title":"Precision medicine in genetic epilepsies: break of dawn?","volume":"17","author":"Reif","year":"2017","journal-title":"Expert Rev. Neurother."},{"issue":"34","key":"10.1016\/j.eplepsyres.2019.03.001_bib0510","doi-asserted-by":"crossref","first-page":"E8077","DOI":"10.1073\/pnas.1804764115","article-title":"Selective NaV1.1 activation rescues Dravet syndrome mice from seizures and premature death","volume":"115","author":"Richards","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"10","key":"10.1016\/j.eplepsyres.2019.03.001_bib0515","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1212\/WNL.0000000000004331","article-title":"Not all SCN1A epileptic encephalopathies are Dravet syndrome: early profound Thr226Met phenotype","volume":"89","author":"Sadleir","year":"2017","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.eplepsyres.2019.03.001_bib0520","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.tins.2018.03.011","article-title":"Progress in understanding and treating SCN2A-mediated disorders","volume":"41","author":"Sanders","year":"2018","journal-title":"Trends Neurosci."},{"issue":"12","key":"10.1016\/j.eplepsyres.2019.03.001_bib0525","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1111\/epi.13596","article-title":"Rapid and safe response to low-dose carbamazepine in neonatal epilepsy","volume":"57","author":"Sands","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0530","article-title":"The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: current evidence and future perspectives","author":"Schubert-Bast","year":"2018","journal-title":"Epilepsy Behav."},{"issue":"20","key":"10.1016\/j.eplepsyres.2019.03.001_bib0535","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","article-title":"Study of intraventricular cerliponase alfa for CLN2 disease","volume":"378","author":"Schulz","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.eplepsyres.2019.03.001_bib0540","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/ng0298-188","article-title":"GLUT-1 deficiency syndrome caused by haploinsufficiency of the blood-brain barrier hexose carrier","volume":"18","author":"Seidner","year":"1998","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.eplepsyres.2019.03.001_bib0545","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.braindev.2015.06.008","article-title":"Efficacy of antiepileptic drugs for the treatment of Dravet syndrome with different genotypes","volume":"38","author":"Shi","year":"2016","journal-title":"Brain Dev."},{"issue":"2","key":"10.1016\/j.eplepsyres.2019.03.001_bib0550","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/epi.13994","article-title":"The prescribable drugs with efficacy in experimental epilepsies (PDE3) database for drug repurposing research in epilepsy","volume":"59","author":"Sivapalarajah","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0555","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.38617","article-title":"Deletion of KCNQ2\/3 potassium channels from PV+ interneurons leads to homeostatic potentiation of excitatory transmission","volume":"7","author":"Soh","year":"2018","journal-title":"Elife"},{"issue":"11","key":"10.1016\/j.eplepsyres.2019.03.001_bib0560","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1111\/epi.13889","article-title":"Dravet syndrome and its mimics: beyond SCN1A","volume":"58","author":"Steel","year":"2017","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.eplepsyres.2019.03.001_bib0565","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/ng1095-201","article-title":"A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy","volume":"11","author":"Steinlein","year":"1995","journal-title":"Nat. Genet."},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0570","series-title":"Stoke Therapeutics Presents Data Showing Single Dose of ASO Therapy Restores Normal Protein Levels in Animal Model of Genetic Epilepsy","author":"Stoke Therapeutics","year":"2018"},{"issue":"1","key":"10.1016\/j.eplepsyres.2019.03.001_bib0575","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/brain\/awy304","article-title":"GRIN2A study group. GRIN2A-related disorders: genotype and functional consequence predict phenotype","volume":"142","author":"Strehlow","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0580","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.13073","article-title":"A deleterious Nav1.1 mutation selectively impairs telencephalic inhibitory neurons derived from Dravet Syndrome patients","volume":"5","author":"Sun","year":"2016","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.eplepsyres.2019.03.001_bib0585","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/dvdy.24582","article-title":"MicroRNA-induced silencing in epilepsy: opportunities and challenges for clinical application","volume":"247","author":"Tiwari","year":"2018","journal-title":"Dev. Dyn."},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0590","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.nbd.2015.02.010","article-title":"Functional and structural deficits of the dentate gyrus network coincide with emerging spontaneous seizures in an Scn1a mutant Dravet Syndrome model during development","volume":"77","author":"Tsai","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0595","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ymgme.2011.11.191","article-title":"Treatable inborn errors of metabolism causing intellectual disability: a systematic literature review","volume":"103","author":"Van Karnebeek","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0600","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.pediatrneurol.2015.12.013","article-title":"Pyridoxine-dependent epilepsy: an expanding clinical spectrum","volume":"59","author":"Van Karnebeek","year":"2016","journal-title":"Pediatr. Neurol."},{"issue":"4","key":"10.1016\/j.eplepsyres.2019.03.001_bib0605","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1159\/000478651","article-title":"A distinctive ictal amplitude-integrated electroencephalography pattern in newborns with neonatal epilepsy associated with KCNQ2 mutations","volume":"112","author":"Vilan","year":"2017","journal-title":"Neonatology"},{"issue":"2","key":"10.1016\/j.eplepsyres.2019.03.001_bib0610","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148129","article-title":"MPX-004 and MPX-007: new pharmacological tools to study the physiology of NMDA receptors containing the GluN2A subunit","volume":"11","author":"Volkmann","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0615","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/acn3.276","article-title":"Pathogenic mechanism of recurrent mutations of SCN8A in epileptic encephalopathy","volume":"3","author":"Wagnon","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"2","key":"10.1016\/j.eplepsyres.2019.03.001_bib0620","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s13311-014-0262-5","article-title":"Genetic biomarkers in epilepsy","volume":"11","author":"Weber","year":"2014","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0625","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1212\/01.wnl.0000435296.72400.a1","article-title":"KCNQ2 Study Group. Extending the KCNQ2 encephalopathy spectrum: clinical and neuroimaging findings in 17 patients","volume":"81","author":"Weckhuysen","year":"2013","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.eplepsyres.2019.03.001_bib0630","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s12264-017-0134-1","article-title":"Ion channel genes and epilepsy: functional alteration, pathogenic potential, and mechanism of epilepsy","volume":"33","author":"Wei","year":"2017","journal-title":"Neurosci. Bull."},{"issue":"2","key":"10.1016\/j.eplepsyres.2019.03.001_bib0635","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.str.2018.11.007","article-title":"How structural biologists and the protein data bank contributed to recent FDA new drug approvals","volume":"5","author":"Westbrook","year":"2019","journal-title":"Structure"},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0640","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.pediatrneurol.2017.01.034","article-title":"Management strategies for CLN2 disease","volume":"69","author":"Williams","year":"2017","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0645","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pediatrneurol.2017.01.025","article-title":"Optimizing the diagnosis and management of Dravet syndrome: recommendations from a North American consensus panel","volume":"68","author":"Wirrell","year":"2017","journal-title":"Pediatr. Neurol."},{"issue":"5","key":"10.1016\/j.eplepsyres.2019.03.001_bib0650","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/brain\/awx054","article-title":"Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders","volume":"140","author":"Wolff","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0655","doi-asserted-by":"crossref","first-page":"e1310","DOI":"10.1542\/peds.2015-1807","article-title":"Incidence of Dravet syndrome in a US population","volume":"136","author":"Wu","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0660","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.neuropharm.2017.05.029","article-title":"Gene therapy and editing: novel potential treatments for neuronal channelopathies","volume":"132","author":"Wykes","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0665","series-title":"XEN496 For Epilepsy","author":"Xenon Pharma","year":"2018"},{"issue":"8","key":"10.1016\/j.eplepsyres.2019.03.001_bib0670","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.braindev.2013.10.004","article-title":"Early clinical features and diagnosis of Dravet syndrome in 138 Chinese patients with SCN1A mutations","volume":"36","author":"Xu","year":"2014","journal-title":"Brain Dev."},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0675","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/nn1754","article-title":"Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy","volume":"9","author":"Yu","year":"2006","journal-title":"Nat. Neurosci."},{"issue":"2","key":"10.1016\/j.eplepsyres.2019.03.001_bib0680","article-title":"Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.eplepsyres.2019.03.001_bib0685","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coph.2014.10.009","article-title":"Allosteric modulators of NMDA receptors: multiple sites and mechanisms","volume":"20","author":"Zhu","year":"2015","journal-title":"Curr. Opin. Pharmacol."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121119300270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121119300270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:41:09Z","timestamp":1760276469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121119300270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":137,"alternative-id":["S0920121119300270"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2019.03.001","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identifying mutations in epilepsy genes: Impact on treatment selection","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2019.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}